Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bearish -35

Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug - Investor's Business Daily

AI-generated analysis

πŸ“‰ Regeneron stock fell 6.2% to close at $686.36 following a disappointing earnings report.

πŸ’° U.S. sales of the company's top revenue driver, Eylea HD, came in at $468 million, below analyst expectations of $476-$502 million.

πŸ“Š Overall adjusted earnings jumped 15% to $9.47 per share, beating estimates of $8.91.

πŸ’΅ Total quarterly sales advanced 19% to $3.61 billion, surpassing the Street's call for $3.48 billion.

πŸ”½ U.S. Eylea total sales declined 10% year-over-year to $941.5 million, while international revenue remains with Bayer.

⚠️ Inventory trends and a lack of prefilled syringe approval are weighing on high-dose Eylea performance ahead of a Q2 regulatory decision.

🚫 A Phase 2 study for the potential lung cancer drug fianlimab failed, resulting in no advancement to Phase 3 development.

πŸ“ˆ Despite the stock slump, Regeneron maintains a Relative Strength Rating above 80 according to market data providers.

πŸ”Ž Analysts note that inventory buildup and approval delays are key headwinds for the company's flagship product line this quarter.

🧾 The biotech firm is set to discuss further developments on regulatory approvals and drug pipelines in future earnings guidance.

Bullish Signals
  • Regeneron posted adjusted earnings of $9.47 a share for the first quarter, beating analyst expectations of $8.91.
  • Sales advanced 19% to $3.61 billion, surpassing the Street's call for $3.48 billion for the period.
  • U.S. Eylea sales declined only in line with expectations at 10%, indicating stability in the company's biggest moneymaker despite high-dose version concerns.
  • Regulators have recently approved longer dosing intervals for Eylea HD to every five months, which could support future revenue streams.
  • The company maintains a strong Relative Strength Rating of 80-plus, signaling sustained investor confidence.
  • U.S. sales of the new high-dose version came in at $468 million against a bullish analyst range of $476 million to $502 million per RBC Capital Markets.
  • Inventory trends may impact Eylea HD specifically, but overall sales performance remains robust and exceeds consensus estimates.
  • A prefilled syringe approval for the drug is expected in the second quarter, potentially enhancing patient convenience and sales potential.
Risk Factors
  • Regeneron stock tumbled 6.2% in the market after reporting light sales of its new high-dose Eylea (Eylea HD), which undercut analyst expectations.
  • U.S. sales of the high-dose Eylea version came in at $468 million, missing the bullish consensus range of $476 million to $502 million predicted by RBC Capital Markets.
  • Total U.S. Eylea sales declined 10% year-over-year to $941.5 million, raising concerns about growth momentum for the company's single biggest moneymaker.
  • Inventory trends are reportedly undercutting the performance of Eylea HD, suggesting supply chain or distribution issues that could impact future revenue.
  • Regulators have yet to approve a prefilled syringe version of the drug, with the decision expected only in the second quarter, delaying a potential convenience benefit.
  • A Phase 2 study of Regeneron's potential lung cancer drug fianlimab failed, as data did not support advancement to Phase 3 development.
  • The failure of the fianlimab trial represents a significant setback for Regeneron's pipeline diversification efforts beyond its core eye disease franchise.
Full Analysis
Regeneron Pharmaceuticals' stock tumbled on Wednesday, closing at 686.36, after reporting weaker-than-anticipated sales for its flagship high-dose Eylea drug. U.S. sales of the new high-dose version came in at $468 million, missing analyst expectations which ranged between $476 million and $502 million as noted by RBC Capital Markets analyst Brian Abrahams. Consequently, total U.S. Eylea sales, which include both low and high doses, declined 10% to $941.5 million, while the company's broader adjusted earnings of $9.47 per share and first-quarter sales of $3.61 billion still beat Wall Street estimates for both metrics, according to FactSet. The stock market reacted negatively primarily due to inventory trends that are undercutting demand for Eylea HD, or high dose. While regulators recently approved longer dosing intervals for the drug every five months for conditions like wet age-related macular degeneration and diabetic macular edema, they have not yet approved a prefilled syringe variant. This decision is expected in the second quarter. Beyond Eylea, Regeneron faced further headwinds as it reported that a Phase 2 study for its potential lung cancer drug, fianlimab, failed to support advancement to Phase 3 development. Despite these specific setbacks, the company maintains a strong relative strength rating of over 80. However, investor sentiment was dampened by the combination of the top-line miss on its bread-and-butter drug and the failure of the fianlimab study, leading to a market reaction that saw shares skid 6.2%. The divergence between overall earnings growth, which jumped 15%, and specific segment performance highlights the mixed operational picture facing Regeneron Pharmaceuticals in the first quarter.